Rapid Medical has secured approval from China’s National Medical Product Administration (NMPA) for its TIGERTRIEVER revascularisation device.

Claimed to be the world’s only adjustable thrombectomy device, TIGERTRIEVER provides patient-specific solutions to remove blood clots from the brain for advancing ischemic stroke treatment.

Leveraging advancements in aerospace engineering, the device facilitates precise control during mechanical thrombectomy.

Its distinctive operation transforms these procedures from passive into an active approach, expediting the capture of clots and potentially cutting the likelihood of vascular injury risk during removal.

In the TIGER multicentre trial, the technology demonstrated three enhancements in the restoration of blood flow to the brain, positive clinical outcomes, and a reduction in emboli to new territories.

These improvements were in comparison to the average results obtained from six important stent retriever trials.

The trial also demonstrated rapid procedure times due to a high rate of success on the first attempt.

Rapid Medical co-founder and CEO Ronen Eckhouse said: “This new approval for TIGERTRIEVER propels treatment for ischemic stroke patients in China.

“We are fortunate to have an excellent partner with MicroPort Scientific Corporation, who understand the need to expand neuro-interventional capabilities and individualized stroke care for these patients.”

Rapid Medical has an exclusive distribution agreement with China-based MicroPort Scientific’s subsidiary MicroPort NeuroTech.

MicroPort NeuroTech president Zhiyong Xie said: “The successful launch of TIGERTRIEVER in China represents another stroke intervention innovation that can be applied in the real world, introducing the concept of tailored thrombectomy using an adjustable stent retriever that allows physicians to navigate procedures and unexpected circumstances with added control.”